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A B S T R A C T
Eating disorders in early childhood are the same frequency in boys and girls. During adolescence eating disorders
are ten (10) times more frequent in girls than in boys. Worrying is the fact that eating disorders are the third chronic ill-
ness among adolescents after obesity and asthma. Depicting this adolescent we tried to show difficulty of treatment of
this disorder, where in the beginning is important to stabilize body weight and prevent somatic damages such as: heart
damage, amenorrhoea, changes in EKG (electrocardiogram) and electrolyte dysbalance that could endanger the life of
patient. Simultaneously it is important to recognize and treat comorbid psychological disturbances such as in this case:
depression, delusions with occasional psychotic reactions combined with unrealistic thinking about the layout of her own
body. There is still no cure for the treatment of eating disorders which are in growing number of reports among male ado-
lescents.
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Introduction
Richard Morton first described Anorexia nervosa
more than 300 years ago, in 1689, as a condition of »a
Nervous Consumption« caused by »sadness, and anxious
cares«. In 1873, two prominent physicians separately de-
scribed Anorexia nervosa; Charles Laségue described it
as »a hysteria linked to hypochondriasis«, and Sir Wil-
liam W. Gull described it as »a perversion of the ego«1.
The causes of eating disorders are not fully under-
stood but we have reasons to believe that biological, psy-
chological and social factors play important role in its de-
velopment and outcome of treatment2. Eating disorders
remain an important health care problem for clinicians
working with children and adolescents3. Diagnostic and
Statistical Manual of Mental disorders (DSM-IV) diag-
nostic criteria for Anorexia nervosa are: 1. refusal to
maintain body weight at or above a minimally normal
weight for age and height, 2. intense fear of gaining
weight or becoming fat, even thought underweight, 3.
disturbance in the way in which one´s body weight or
shape is experienced, undue influence of body weight or
shape on self-evaluation, or denial of the seriousness of
the current low body weight, 4. in postmenarcheal fe-
males, amenorrhoea, i.e. the absence of at least three
consecutive menstrual cycles. A woman is considered to
have amenorrhea if her periods occur only following hor-
mone, e.g., estrogen administration4 Amenorrhea is a
DSM-IV criterion for the diagnosis of Anorexia nervosa
and reflects weight and nutritional status rather than
providing useful diagnostic information5. Anorexia ner-
vosa has the highest mortality of any psychiatric disor-
der. It has prevalence of about 0.3% in young women. It is
more than twice as common in teenage girls, with an av-
erage age of 15 years; 80–90% of patients with anorexia
are females. It is the most common cause of weight loss
in young women and of admission to child and adolescent
hospital service. Most of the causes of Anorexia nervosa
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are immense distress and frustration in careers and
professions6.
Risk factors mostly are: women gender, family factors,
biological vulnerability, individual psychological factors
such as perfectionism and obsessive behavior, lack of con-
fidence, feeling of inadequacy, depression, alcohol and
drug use, genetic vulnerabilities, individual behavior such
as dieting, involvement in activities or professional con-
trol-gymnastic, ballet, wrestling, actors, models, dysfun-
ction of neurotransmitters (norepinephrine or seroto-
nin), cultural risk factors such as living in industrialized
country and imperative to being beautiful, stressful life
events or sexual risk factors (Table 1)7. The multidimen-
sional approach to the ethiopathogenesis of eating disor-
ders include genetic, biological, psychosocial effects and
premorbid personality markers8. Leptin which was dis-
covered only a decade earlier, is a peptide that informs
hypothalamic areas about the energy balance of the body.
New scientific researches has suggested a possible role of
leptin in eating disorders9. The younger age group is
more likely to present with Anorexia nervosa, while the
older adolescents can present with either anorexia or
bulimia nervosa. Failure of outpatient management re-
quires hospitalization for nutritional rehabilitation with
close monitoring of fluid and electrolyte status to prevent
the development of refeeding syndrome. Family involve-
ment is vital, particularly in the younger patients, with
ongoing family therapy offering the best outcomes10.
Olanzapine has proven to be as effective drug in
maintaining body weight as well as in alleviation delu-
sions and unrealistic perceptions about own body and
body weight, what was confirmed according to data in
the literature in recent years.
Case Report
D. ^. is 15 years old girl, who attend first class of sec-
ondary school. She was living with her parents and twin
sisters seven years old. Mother is unemployed, father is
employed. One of the twin sisters is under neurologically
treatment because of epileptic seizures, mother is under
treatment by oncologist because of breast cancer. Early
psychomotoric development was regular, she established
regular control of sphincters, spoke up and walked on the
feet properly. During elementary school she was excel-
lent pupil, with good manner. During early childhood on
physical plan, she was not seriously ill, she denied any
traumatic injury of the head, convulsions and distur-
bances of consciousness. Family relationships were in
harmony alleged by the parents, mother was occasionally
tended to anxious and depressive symptomatology, re-
lated to her own malignant disease.
Year and the half before the admission in the Univer-
sity Department of child and adolescent psychiatry, she
began an intensive diet, after observation by her peers
that she was an overweight. She has lost 30 kilograms
during time period of 10 to 12 months, and last 3 months
she has eaten minimal quantity of food. Alleged by the
family, she ate strictly determined food, mostly with
lower caloric values, she has insisted on very specific type
of bread, she has chosen dishes, of the fruit she has taken
only apples, she exercised intensively, she was attempted
to walk as much as possible. Beside changes related to
food, we observed disturbances in psychological function-
ing: she dragged from the surrounding, she was going
out with her peers less often, time spent mostly in her
room, with mother talked only about food, she verbalized
fear of fattening. Parents were expressed concern be-
cause she was very weak in last time, she was barely
standing on her feet and looked very exhausted. Also had
all the excellent grades in school, but school authorities
have expressed concern for her health. In august twenty-
-fifth of the 2008, outpatient review was made on Pediat-
ric clinic and has proposed hospital treatment. First hos-
pitalization on Psychiatric clinic for child and adolescent
psychiatry was in April 2008. In somatic and neurologi-
cal status we have observed that the patient was pale,
tired, with cold skin on touch, lanugo hairs over the skin,
halos around the eyes, external mucoses were pale,
weights 44 kilograms, heights 170 centimeters, with
body mass index of 15.2. According to normal range
(18.5–25.0) our patient is severely underweight. A body
mass index nearing 15 is usually used as an indicator for
starvation and the health risks involved, with a BMI
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TABLE 1
RISK FACTORS ASSOCIATED WITH ANOREXIA NERVOSA
Risk factors Main features











defence of oral fantasies
4. Mother-child relationship absolute authority of the
mother
passive father
5. »Crisis« of identity the struggle for self respect of
their own identity
6. The impact of »modern«
life style
imperative of beauty, thinness,
an ideal of youth
7. Selection of occupations
that required thinness
ballet dancer, gymnast, jockey,
dancer
8. Relationship within the
family
overly protective parents, con-
trol daughter, avoid separation
9. Personality traits 68% have major depressive
disorder
65% have anxiety disorder
(26% obsessive compulsive
disorder, 34% social phobia)
10. »C« Cluster of personality
disorder




<17.5 being an informal criterion for diagnosis of An-
orexia nervosa6. In psychological status: decreased mood,
abulic, anhedonic, resigned, with insufficient criticism to
her condition, denied suicide thoughts, not psychotic. Af-
ter admission of the patient, broad laboratory investiga-
tion was done: complete blood count, iron, C-reactive
protein (CRP), liver enzymes tests, sex hormones, cor-
tisol, adrenocorticotropic hormone (ACTH), thyroid hor-
mones (TH), C-peptide, and all of these tests were in the
normal range. Creatinine was 71 mmol/L (normal range:
18–62 mmol/L), unsaturated iron binding capacity (UIBC)
25.1 mmol/L (normal range:31.0–72.0 mmol/L), transfer-
rin saturation (TSAT) 37 mmol/L (normal range:6–33
mmol/L). She was examined by pediatrician, who has rec-
ommended diet with higher caloric intake and Ensure
plus potion. Because of amenorrhoea, which has occured
a year before the hospital treatment, she was investi-
gated twice time by gynecologist, who did not prescribe
pharmacological treatment. Psychological testing display-
ed that the she was above average intelligence for adoles-
cent, without cognitive disturbances, but with nutrition
disturbance (anorexia), followed with depressive symp-
toms, lower self esteem, obsession and social withdrawal.
In treatment plan beside intensive psychotherapy and
sociotherapy also was included pharmacological treat-
ment with antidepressant, because of marked clinical de-
pressing picture. Pharmacological treatment was started
with escitalopram five (5) mg per day, with increment of
dose on ten (10) mg per day, after one week. Gradually,
we have observed discrete shift on willing-affective plan,
patient became more critical to her own condition, but
still with a resistance to taking large quantities of food.
After discharge from the Clinic, it was continued ambu-
latory care.
First check examination after discharge (sixth
month)-adolescent was still resigned, apathetic, she ate
minimal amount of selected food, refused intake of food
with higher caloric values, she isolated herself and dra-
gged herself from peers. Dose of escitalopram was in-
creased on twenty (20) mg in the morning. Second check
examination after discharge (seventh month)-without
shift in psychic status, body weight was 44.5 kg, labora-
tory test displayed increased liver transaminases, aspar-
tate transaminase (AST) 94, normal range:14–22 U/L;
alanine transaminase (ALT) 177, normal range:10–20
U/L. After doing some other tests (ultrasound of liver
and markers for viral hepatitis B and C) it was concluded
that was slightly and transitory liver lesion. We have put
out escitalopram from therapy. Given the deterioration
in the mental status and body weight of 45 kilograms, it
was again recommended hospital treatment, but family
rejected it. We have started pharmacological treatment
with fluvoxamine in dose of fifty (50) mg in the evening,
but because of increased liver transaminases this medi-
cation also was put out of therapy. Third check examina-
tion after discharge (ninth month)-adolescent success-
fully passed entrance examination for secondary medical
school, although her first choice was general-program
secondary school. From parents we have found out that
adolescent »was in fear that she will not pass entrance
examination for general-program secondary school« and
self-initiatively decided to enter into secondary medical
school. Adolescent cited as a reason for her choice was
»her will to help other people«. Her weight was stable,
appetite was still weak, it was observed her preoccupa-
tion with nutrition and foodstuff. We have put in therapy
sulpiride capsules in dose 100 mg twice a day, considering
the fact that this medicine does not affect the metabo-
lism, does not increase liver transaminases, in lower
doses has good antidepressant effect and increase appe-
tite. Fourth check examination after discharge (tenth
month) – it was observed deterioration in mental status,
she was very exhausted, hardly stood on her legs, looked
malnourished (body weight 43 kilograms, body height
170 cm), body mass index (BMI) 14.87 directing the mal-
nutrition, very uncritical to her condition, not motivated
for treatment, rejected staying on Clinic. From parents
we found out that she was extremely tense, irritable,
changed mood easily, conflicts were often if parents does
not buy strictly specific food etc. In school she still had
excellent grades, but she did not fit well in their peers,
mostly she was alone, she did not go out, during the day
was quite asleep. Self-initiatively decreased taking of En-
sure Plus potion from six to two doses. Ensure plus is a
source of complete, balanced nutrition that provides con-
centrated calories, protein and fiber to help patients gain
or maintain weight. One Ensure Plus has approximately
350 calorie density so daily income in our case was 2000
calories (4 to 6 per day). Ensure Plus may be substituted
for Ensure if the patient needs to drink 3 or 4 cans of reg-
ular Ensure to reach a weight goal. Fifth check examina-
tion (tenth month) – in treatment was included atypical
antipsychotic drug olanzapine tablets in dose of five (5)
mg in the morning with sulpiride two hundred (200) mg
divided in two doses. During examination it was ob-
served that the patient was physically and mentally ex-
hausted, in mental status delusions and unrealistic attitu-
des about external appearance were presented, com-
pletely uncritical to her external appearance, she consid-
ered that she was not »thin« enough, persistently has re-
jected taking food in more meals, mostly has consumed
apples. She was very abulic, not motivated for therapeu-
tic process, has rejected taking medicines. Hospital treat-
ment was recommended. Second hospitalization at the
clinical department for child and adolescent psychiatry
(13.10.–17.11.2008.) – in psychiatric status depressive
mood was dominated, ambivalent attitude according to
suicide, delusions, possessed ideas about external physi-
cal appearance, with general physical exhaustion as reac-
tion on visible undernourishment (body weight 43 kilo-
grams, body height 170 centimeters). It was done compre-
hensive somatic investigation and retest by psychologist:
electroencephalography (EEG) examination (normal), con-
trol complete blood count (mild microcytic anemia), sex
hormones: follicle-stimulating hormone (FSH), luteini-
zing hormone (LH), estradiol, progesterone-all were in
normal range. She was examined by cardiologist-except
bradycardia on electrocardiogram (EKG) test, all param-
eters were normal. Thyroid hormones were in normal
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range. Pediatric examination: Ensure plus potions up to
2000 calories per day. She has been on continuous psy-
chotherapy with cognitive behavioral approach individu-
ally. Along with the surveillance of medical staff in seven
days polyvitaminic therapy with glucose and vitamines B
and C was udertaken. Daily menu was made up accord-
ing pediatric recommendations up to 2000 calories per
day. Dose of olanzapine was increased on ten (10) mg di-
vided in two doses with sulpiride tablets. The aim of ther-
apy was to prevent further decrease on body weight, but
also confrontation with the general state of the goal to
achieve more critical attitude to disease and external ap-
pearance. Considering that the patient occasionally dis-
played symptoms of psychotic behavior as a consequence
of longtime starvation and insufficiently intake of energy
(glucose), monitoring of patient and her behavior was en-
hanced. Over a period of psychotherapeutic discussions
with adolescent, we heard that she was not satisfied with
school choice recently, she was not well suited in second-
ary medical school, most of her girlfriends were enrolled
in gymnasium. She was not seen herself as skinny, she
was thought that she has finally reached desired weight.
During pediatric examination, she was informed on pos-
sibility of coercively treatment with nasogastric probe, if
she still continued to reject food intake, but without sub-
stantial effect on her attitude on external appearance.
Diagnostically it was an impression that she has progres-
sively proceeded to clinical picture of psychotic reaction.
Dose of olanzapine was increased on fifteen (15) mg per
day, adding valproate in dose of three hundred (300) mg
in the evening. Sulpiride was excluded from therapy. Re-
test by psychologist from tenth month displayed the
persistence of disturbances related to test from fourth
month of 2008. year, when adolescent verbalized fear of
thickness, was feeling guilty after food intake, but par-
tially with critical attitude on her relation to food, raised
social anxiety and inadequate strategies for stress cop-
ing. Gradually, there was increase on body weight and
four weeks after hospital treatment body weight was
forty seven (47) kilograms. Patient was further persisted
on her attitudes to the food. Because of school duties she
was discharged in partially improved condition at the re-
quest of her parents, against advice of physicians. First
control examination after hospital treatment – she had
stable body weight, but she was still ambivalent, abulic,
socially isolated, with often mood oscillations, tended to
aggressive behavior toward her mother, related to food
selection because mother has cooked equally for her and
the rest of the family. She has avoided intake of some
food, mostly she has eaten apples and integral pastry.
Laboratory findings: liver enzymes AST, ALT, gamma
glutamyltransferase (GGT) were in normal range. Sec-
ond control after hospital treatment-she had stable body
weight (body weight 47 kilograms, body height 170 centi-
meters), with excellent grades on school semester, dis-
crete shift on willing-affective plan, occasionally mood
oscillations, she has expressed tiredness and drowsiness.
During examination we have observed cold skin, lanugo
hairs over the skin and face pallor. It was still present
amenorrhoea with occasionally constipations. Patient
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TABLE 2
COURSE OF THERAPEUTIC INTERVENTIONS
August 2007, 73 kg, 170 cm
April 2008,
43 kg, 170 cm
The first hospitalization in a psychiatric
clinic
Ensure Plus (4-6 times a day)
Escitalopram
June 2008 The first control examination Escitalopram 10 mg daily
Escitalopram 20 mg daily in two divided doses after three
weeks
July 2008 The second control examination Escitalopram excluded from therapy
Fluvoxamin 50 mg in the evening was included
September 2008 The third control examination Sulpiride 100 mg daily in two doses
September 2008 The fourth control examination Sulpiride 200 mg daily
Ensure Plus (two times daily)
October 2008. The fifth control examination Olanzapine tablets (orodispersible) 5 mg in the morning
November 2008 The second hospitalization Olanzapine 10 mg daily divided in two doses
Polyvitamin therapy with 5% glucose and vitamins B and C
for 7 days
Ensure plus (2000 calories per day)
November/December The second hospitalization Olanzapine 15 mg daily divided in two doses
Valproate 300 mg in the evening
December The first control examination after second
hospitalization
Olanzapine 15 mg daily
Valproate 300 mg daily
January 2009,
49 kg, 170 cm
The second control examination after second
hospitalization
Olanzapine 15 mg daily
Valproate 300 mg divided in two doses
Escitalopram 10 mg in the morning
was told that is necessary to achieve gain in body weight,
because of production of sex hormones and establishing
of regular menstrual cycles. Mother and father was ex-
plained possibility of referral adolescent to Clinic for psy-
chological medicine, because of examination and possible
agreement about family therapy (Table 2). Third control
examination after hospital treatment: she had stable
body weight, partially more critical to external appear-
ance, but also pronounced depressive clinical picture. It
was still recommended to continue with present therapy.
Laboratory test: total cholesterol (TC) 4.8 mmol/L, high
density lipoprotein (HDL)-cholesterol 1.07 mmol/L, trigly-
cerides 1.03 mmol/L, low density lipoprotein (LDL)-cho-
lesterol 3.3 mmol/L, iron 9 mmol/L, blood urea nitrogen
(BUN) 5.2 mmol/L, creatinine 77 mmol/L, ALT 30 U/L,
GGT 24 U/L, CRP 1.5 mg/L-all in normal range.
Disscusion
The core psychological feature of Anorexia nervosa is
the extreme overvaluation of shape and weight. People
with anorexia also have the physical capacity to tolerate
extreme self imposed weight loss and many people with
Anorexia nervosa use over-exercise and overactivity to
burn calories. Our adolescent has met all criteria with
amenorrhoea which has existed four months prior to hos-
pitalization on Clinic and body mass index of 14.5.
Individuals with Anorexia nervosa tend to have obses-
sive-compulsive and dysphoric mood, high constraint,
constriction of affect and emotional expressiveness, an-
hedonia, and asceticism. Such symptoms often begin in
childhood, before the onset of an eating disorder, and per-
sist after recovery, suggesting that these are traits that
create vulnerability for developing eating disorder11. Con-
siderable evidences suggest that altered brain serotonin
5-hydroxytryptamine (5-HT) function contributes to dy-
sregulation of an appetite, mood and impulse control in
Anorexia nervosa. Stress and/or cultural and societal
pressures may contribute by increasing anxious and ob-
sessive temperament. Individuals with Anorexia nervosa
may discover that reduced dietary intake, by reducing
plasma tryptophan availability is a means by which they
can modulate brain 5-HT functional activity and anxious
mood12. Resent studies have hypothesized that perinatal
complications might increase the risk of developing eat-
ing disorders. The presence of signs of neonatal dy-
smaturity at birth seems to influence the development of
high levels of harm avoidance in eating disorders13. Ado-
lescents with Anorexia nervosa are usually high achiev-
ers and are often involved in a number of extracurricular
activities such as tutoring, volunteer work and commu-
nity leadership, they tend to be perfectionists, have in-
ternalizing coping styles and obsessive behaviors. The
family dynamics commonly seen in families of teenagers
with Anorexia nervosa include conflict avoidance, undue
degrees of enmeshment with either parent, rigid and
overprotective parenting14. Girls with higher BMI, who
accepted societal standards of thin-ideal, perceived major
social pressure to be thin throughout direct and persua-
sive comments designed to establish the importance of
dieting and develop eating habits15. By het-
ero-anamnestic data from parents we have found out
that disturbances in adolescent were began in the period
when the mother began treatment by oncologist because
malignant disease on her breast. In this period, mother
was also under psychiatric treatment because of depres-
sive symptoms, without capacity to recognize what was
happening with her daughter. Also, one of the youngest
daughter has epilepsy and during that stressful period
her condition also get worse. All that stressful events
have made our adolescent more anxious in actual situa-
tion. Family and her friends have described adolescent as
obsessive in carrying out her tasks and decent girl, with
excellent grades in all classes. Always trying to be the
best in everything. Naturally, she has greater
osteomuscular composition and loss of thirty (30) kilo-
grams during last year, started to worry family and
school authorities, and after the diagnostic process by pe-
diatrician, they came to Clinical department for child
and adolescent psychiatry. Psychodynamically, can be
taken into consideration the feeling of intense worry for
the mother and changed the school selection. Adolescent
originally wanted to enter high school language but she
chose nursing school. The treatment of eating disorders
as Anorexia nervosa is based on multimodal approach. In
some cases escitalopram may reduce depression and anx-
iety during weight gain. The pharmacological options for
Anorexia nervosa are very limited. Peptide hormones are
increasingly being evaluated for eating disorder treat-
ment, including ghrelin agonists, neuropeptide Y1 and 5
antagonist, orexin receptor antagonists, corticotropin-re-
leasing factor receptor 2 antagonist, histamine 3 antago-
nists, melanocortin 4 receptor antagonists, beta 3-adre-
noreceptor agonists, 5-hydroxytryptamine 2A antagonists
and growth hormone agonists16.The decision to hospital-
ize a patient is based on the patient’s medical condition
and the amount of structure needed to ensure patient’s
cooperation. Anorexia nervosa patients who are 20 per-
cent bellow the expected weight for their height are rec-
ommended for inpatient programs, and patients who are
30 percent below their expected weight require psychiat-
ric hospitalization for 2 to 6 months4. A cardiovascular
risk profile might be expected in Anorexia nervosa due to
low body weight and dietary fat intake17. It is an eating
disorder which, in case of life-threatening complications,
requires admission to the intensive care unit. Prolonged
electrolyte disturbances in Anorexia nervosa, catabolism
and insufficient immunity are main factors for develop-
ing an acute inflammation, as well as some other compli-
cations such as cardiorespiratory failure, nosocomial in-
fections and sepsis with multiple organ failure18. Taking
into account very low body mass index (BMI) of 14 which
was pointed to extreme malnutrition, amenorrhoea and
poor somatic condition followed with bradycardia in
EKG (electrocardiogram), anemia with hypothermia,
lanugo hairs over skin and bad psychological condition,
we have taken position on hospitalization in Clinic. At
first hospitalization we have noticed great resistance and
loss of motivation in relation to the therapeutic ap-
K. Dodig-]urkovi} et al.: The Role of Olanzapinum in Anorexia nervosa, Coll. Antropol. 34 (2010) 3: 1093–1099
1097
proaches, and distorted image of her own appearance
and body weight, followed with statements »I am not
skinny, I have a good body weight now and need to main-
tain it«. We have decided for less aggressive psycho-
therapeutic approach considering earlier confrontation
with pediatrician led to an aggravation of her mental
state. The major characteristics patients with Anorexia
nervosa are: 25% loss of body weight, weight phobia, pre-
occupation with food, body image disturbances and many
others medical conditions: bradycardia, hypotension, de-
hydration, hypothermia, electrolyte abnormalities, ame-
norrhoea, metabolic changes and abdominal distress.
Anorexic adolescents resist treatment and may die if not
cured19. The eating disorders as Anorexia nervosa and
bulimia nervosa present with comorbidity in a number of
important areas, including depression, bipolar disorder,
anxiety disorder (obsessive-compulsive disorder, panic
disorder, social anxiety disorder and other phobias, and
post-traumatic stress disorder) and substance abuse20.
The aims of medical treatment are to promote body-
weight gain and nutritional recovery. Psychiatric goals
are address the psychosocial precipitants, treat comorbid
mood disorders and assist the patient to develop alterna-
tive coping skills21. While serotonin, dopamine and pros-
taglandin promote the ingestion of food, by contrast,
neuropeptide Y, norepinephrine, GABA and opiod pep-
tides inhibit food ingestion, causing the occurrence of
eating disorders. Mood stabilizers as lithium, anxiolytics,
serotonin and noradrenalin reuptake inhibitors, and
antipsychotic drugs are often used in the treatment of
eating disorders22. Megestrol acetate is currently used to
improve appetite and to increase weight in cancer-associ-
ated anorexia and 1993 was approved by USA Federal
Drug Administration for the treatment of anorexia,
cachexia or unexplained weight loss in patients with
AIDS. Megestrol may interfere with the normal men-
strual cycle in women and also may cause many other
side effects, and in our patient this drug was not a choice
for treatment23. Whereas antidepressants have not been
proven to be useful in promoting weight gain, they can
play a role in the treatment of comorbid conditions such
as a major depression, obsessive-compulsive disorder or
other anxiety disorders. Selective serotonin reuptake in-
hibitors may help prevent relapse in some patients with
Anorexia nervosa, once weight restoration has been
achieved. Atypical antipsychotics as olanzapine, facili-
tate weight restoration and decrease eating-focused and
weight-focused anxiety. Those drugs should not be used
as a first-line treatment but could be tried in patients
whose condition is refractory to treatment or high-risk
patients. Cardiac and liver functions should be moni-
tored and caution should be exercised in the use of drugs
that may compromise cardiac function. Drugs that pro-
long QT interval or that lower the seizure threshold
(bupropion) should also be avoided24. Results showed
that olanzapine, an atypical antipsychotic, is known to
result in weight gain and suggested that olanzapine may
be safely used in achieving more rapid weight gain and
improvement in obsessive symptoms among women with
Anorexia nervosa25. Anorexia nervosa patients often
show extreme hypophagia and excessive physical activity.
Olanzapine treatment reduced physical activity in hyper-
activity Anorexia nervosa patient26. Excessive physical
activity is commonly described as a symptom of Anorexia
nervosa and suppression of hyperactivity by olanzapine
in anorectic patients as well as in ABA rats suggested a
role of dopamine and serotonin in this trait. These data
support a role for dopamine in anorexia associated hy-
peractivity27. In our case the main therapeutic goal was
to prevent further weight loss and possible somatic dam-
ages (heart complications) and with combining of olan-
zapine and sulpiride we have achieved an increase in
body weight of about four kilograms in ten weeks. Sul-
piride as a drug in smaller doses has an antidepressant
effect and in higher doses has antipsychotic effect, and
considering that it does not affect increase of liver trans-
aminases, we have it chosen as a drug of choice in the
treatment of low mood, lethargy and loss of motivation.
Because sulpiride has an amenorrhoea as a side-effect,
after the initial treatment we have replaced it with
valproate as a mood stabilizer28. Sulpiride as an antipsy-
chotic blocks dopamine 2 recepors in tuberoinfundibular
patway. This causes plasma prolactin concentration to
raise, also galactorrhea and amenorrhoea, so we ex-
cluded sulpiride in further therapeutic plan29. Hyper-
prolactinemia is also one of the clinical sign in Anorexia
nervosa, primary because of hypothalamic dysfunction,
but also because of overactivation of dopamine system
that can produce eating deficit. Valproate may be effec-
tive in treating patients with eating disorders such as
Anorexia nervosa and bulimia. It is used to treat an asso-
ciated psychiatric disorder (mood) but also valproate is
used for weight gain30. With olanzapine in dose of ten
(10) mg on daily basis and the occasional infusion of glu-
cose and B vitamines, we have kept body weight of ado-
lescent. Simultaneously we have alleviated symptoms of
psychotic behavior: we have decreased delusions of her
own appearance and body weight as well as the irrational
food selection and caloric values of certain foods. On sev-
eral occasions we did examination by cardiologist and en-
docrinologist. Adolescent is still in continuous psycho-
therapeutic approach, where with the help of cognitive
behavioral method is trying to influence the behavior of
adolescent in relation to food habits. It is necessary to or-
ganize family psychotherapeutic approach as well as sup-
port from family and school authorities. Prognosis and
further course of disease is uncertain and presenting
great challenge for every physician who is involved in the
treatment of these patients.
Conclusion
Anorexia nervosa has the highest mortality of any
psychiatric disorder31. For the treatment of Anorexia
nervosa, the key elements are optimal pharmacological
management, cognitive therapy and family therapy. Nu-
tritional rehabilitation and weight restoration are essen-
tial. In this case we described the clinical features of An-
orexia nervosa with psychotic elements and optimal
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pharmacological treatment in order to achieve weight
gain and stabilization of some somatic parameters. Re-
cently, we still do not have effective drugs to treat an-
orexia.
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PRIKAZ TERAPIJSKOG PLANA U LIJE^ENJU ANOREXIJE NERVOZE SA PSIHOTI^NIM
ELEMENTIMA U ADOLESCENTICE
S A @ E T A K
Poreme}aji prehrane su u ranom djetinjstvu jednako u~estali kod dje~aka i kod djevoj~ica. Za vrijeme adolescencije
se oko deset puta ~e{}e javlja kod djevojaka. Zabrinjava podatak da su poreme}aji prehrane tre}a kroni~na bolest kod
adolescenata, nakon debljine i astme. Mla|i adolescenti i adolescentice ~e{}e oboljevaju od anoreksije, dok stariji ado-
lescenti u jednakoj mjeri i od anoreksie ili bulimije. Prikazom ove adolescentice smo nastojali ukazati na te`inu lije~enja
ovog poreme}aja gdje je u po~etku va`no stabilizirati tjelesnu te`inu i sprije~iti somatska o{te}enja kao {to: o{te}enje
srca, amenoreja, promjene u EKG nalazu i elektrolitski disbalans koji bi mogli `ivotno ugroziti pacijenticu. Istovremeno
je va`no prepoznati i lije~iti i komorbidne psihi~ke poreme}aje kao {to su u ovom slu~aju: depresija, deluzije, uz po-
vremene psihoti~ne reakcije vazano uz nerealna razmi{ljanja o izgledu vlastitog tijela. Jo{ uvijek ne postoji lijek za
lije~enje ovog poreme}aja koji se u sve ve}em broju javlja i me|u adolescentima mu{kog spola.
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